When it comes to drug pricing, the Trump and Biden-Harris administrations both have some very modest wins to tout.
As director of the Health Outcomes, Policy, and Evidence Synthesis group[1] at the University of Connecticut School of Pharmacy, I teach and study[2] about the ethics of prescription drug prices and the complexities of drug pricing[3] nationally.
Delving into the presidential candidates’ successes on a number of...